Hyperactivation of the pathway accelerates intestinal tumourigenesis driven by Adenomatous polyposis coli loss (Apcmin/+ mice) (Luo et al., 2009), while a genetic background of partial loss-of-function of EGFR (Roberts et al., 2002) or small-molecule inhibitor treatment reduces cancer incidence (Roberts et al., 2002; Torrance et al., 2000). Here, EGFR is linked to cancer.